Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus

Junichi Kodama, Noriko Seki, Yojiro Ojima, Keiichiro Nakamura, Atsushi Hongo, Yuji Hiramatsu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus. Study design: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study. Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included. Results: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7%) underwent combination chemotherapy. Disease recurrence occurred in 10 patients within a median time of 17 months. Histologic grade 3 was an independent prognostic factor for both disease-free and overall survival rates. Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002). The 5-year disease-free and overall survival rates for these individuals was 92.3%, a value significantly higher than those in patients who had not undergone chemotherapy (50.0%). Conclusions: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.

Original languageEnglish
Pages (from-to)76-80
Number of pages5
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume131
Issue number1
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Adjuvant Chemotherapy
Endometrial Neoplasms
Uterus
Survival Rate
Disease-Free Survival
Uterine Diseases
Epirubicin
Carboplatin
Etoposide
Paclitaxel
Combination Drug Therapy
Gynecology
Cyclophosphamide
Cisplatin
Obstetrics
Cell Biology
Neoplasms
Recurrence
Drug Therapy

Keywords

  • Adjuvant chemotherapy
  • Endometrial cancer
  • Histologic grade
  • Prognostic factor
  • Surgical staging

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. / Kodama, Junichi; Seki, Noriko; Ojima, Yojiro; Nakamura, Keiichiro; Hongo, Atsushi; Hiramatsu, Yuji.

In: European Journal of Obstetrics Gynecology and Reproductive Biology, Vol. 131, No. 1, 03.2007, p. 76-80.

Research output: Contribution to journalArticle

@article{7ac9bc4f8cb84af5941c2e7bdc435c89,
title = "Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus",
abstract = "Objective: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus. Study design: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study. Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included. Results: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7{\%}) underwent combination chemotherapy. Disease recurrence occurred in 10 patients within a median time of 17 months. Histologic grade 3 was an independent prognostic factor for both disease-free and overall survival rates. Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002). The 5-year disease-free and overall survival rates for these individuals was 92.3{\%}, a value significantly higher than those in patients who had not undergone chemotherapy (50.0{\%}). Conclusions: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.",
keywords = "Adjuvant chemotherapy, Endometrial cancer, Histologic grade, Prognostic factor, Surgical staging",
author = "Junichi Kodama and Noriko Seki and Yojiro Ojima and Keiichiro Nakamura and Atsushi Hongo and Yuji Hiramatsu",
year = "2007",
month = "3",
doi = "10.1016/j.ejogrb.2006.01.006",
language = "English",
volume = "131",
pages = "76--80",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus

AU - Kodama, Junichi

AU - Seki, Noriko

AU - Ojima, Yojiro

AU - Nakamura, Keiichiro

AU - Hongo, Atsushi

AU - Hiramatsu, Yuji

PY - 2007/3

Y1 - 2007/3

N2 - Objective: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus. Study design: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study. Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included. Results: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7%) underwent combination chemotherapy. Disease recurrence occurred in 10 patients within a median time of 17 months. Histologic grade 3 was an independent prognostic factor for both disease-free and overall survival rates. Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002). The 5-year disease-free and overall survival rates for these individuals was 92.3%, a value significantly higher than those in patients who had not undergone chemotherapy (50.0%). Conclusions: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.

AB - Objective: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus. Study design: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study. Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included. Results: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7%) underwent combination chemotherapy. Disease recurrence occurred in 10 patients within a median time of 17 months. Histologic grade 3 was an independent prognostic factor for both disease-free and overall survival rates. Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002). The 5-year disease-free and overall survival rates for these individuals was 92.3%, a value significantly higher than those in patients who had not undergone chemotherapy (50.0%). Conclusions: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.

KW - Adjuvant chemotherapy

KW - Endometrial cancer

KW - Histologic grade

KW - Prognostic factor

KW - Surgical staging

UR - http://www.scopus.com/inward/record.url?scp=33847137283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847137283&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2006.01.006

DO - 10.1016/j.ejogrb.2006.01.006

M3 - Article

C2 - 16459012

AN - SCOPUS:33847137283

VL - 131

SP - 76

EP - 80

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -